
MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
Adding to its latest string of deals Pfizer has acquired vaccine developer Redvax – the pre-clinical arm of Swiss company …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

